How clinicians are using clonoSEQ in routine practice
For patients with CLL, myeloma, or B-ALL, clonoSEQ MRD testing is one method of many tests which may help inform decisions to reduce or stop treatment. Learn how clonoSEQ can be implemented in clinical practice from this selection of case studies in our library.
MRD Helps Predict Outcomes and Informs Treatment Decision for a Myeloma Patient
MRD Helps Predict Outcomes and Informs Transplant Decision for an ALL Patient
MRD Helps Predict Outcomes and Informs Maintenance Treatment for a Myeloma Patient
MRD to Support Treatment Planning in a Young, High-Risk ALL Patient
MRD to Motivate a Myeloma Patient to Augment Therapy
Initiating Consolidation Prior to Transplant Based on MRD Positivity in Acute Lymphoblastic Leukemia
MRD-Informed Treatment Decisions in a Patient with Relapsed Myeloma
MRD to Assess Response and Inform Transplant Decision in a Relapsed ALL Patient
Individualizing Transplant Decisions Based on Depth of Response in Myeloma
MRD-Based Risk Assessment in Multiple Myeloma to Inform Maintenance Discontinuation
MRD to Assess Depth of Response in a High-Risk Myeloma Patient
MRD results are increasingly recognized as an important facet of care in multiple myeloma. Learn more about how clonoSEQ can be used for patients with myeloma.
MRD results are increasingly recognized as an important facet of care in CLL. Learn more about how clonoSEQ can be used for patients with CLL.
In pediatric B-ALL, MRD results are routinely incorporated in clinical care. Learn more about how clonoSEQ can be used for patients with ALL.
In AYA B-ALL, MRD results are routinely incorporated into clinical care. Learn more about how clonoSEQ can be used for patients with ALL.
In adult B-ALL, MRD results are routinely incorporated in clinical care. Learn more about how clonoSEQ can be used for patients with ALL.
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.
Submit a Case Study
Do you have a case study in which MRD results were used to inform care decisions? If you’d like to share with Adaptive for inclusion on this site, fill out an online case form and submit for review by our Medical Affairs Team, or download the form and email a completed version to firstname.lastname@example.org.